24 articles for WF Huffman
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
9
Potent vasopressin antagonists modified at the carboxy-terminal tripeptide tail.
Research and Development Division
4
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
TBA
47
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Glaxosmithkline
9
Cyclic enkephalin analogues containing alpha-amino-beta-mercapto-beta,beta-pentamethylenepropionic acid at positions 2 or 5.
Smith Kline and French Laboratories
17
Structure-activity relationships in 3-oxo-1,4-benzodiazepine-2-acetic acid GPIIb/IIIa antagonists. The 2-benzazepine series
TBA
6
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonists.
Glaxosmithkline
7
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic.
Smithkline Beecham Pharmaceuticals
5
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model.
Smithkline Beecham Pharmaceuticals
21
Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists.
Smithkline Beecham Pharmaceuticals
14
Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists.
Smithkline Beecham Pharmaceuticals
10
Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
Smithkline Beecham Pharmaceuticals
5
A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of gamma-turn mimetics into a model substrate.
Smithkline Beecham Pharmaceuticals
4
Potent non-peptide fibrinogen receptor antagonists which present an alternative pharmacophore.
Smithkline Beecham Pharmaceuticals
2
A check on rational drug design: crystal structure of a complex of human immunodeficiency virus type 1 protease with a novel gamma-turn mimetic inhibitor.
Smithkline Beecham Pharmaceuticals
4
Design, synthesis, and biological activity of a peptide mimic of vasopressin.
Smith Kline and French Laboratories
4
Potent antagonists of vasopressin antidiuretic activity that lack the beta,beta-cyclopentamethylene-beta-mercaptopropionic acid substitution at position 1.
TBA
7
Novel vasopressin analogues that help define a minimum effective antagonist pharmacophore.
TBA
6
A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity.
Smith Kline & French Laboratories
48
Aniline derivative, pharmaceutical composition containing same, and use thereof
Kissei Pharmaceutical
70
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Glaxosmithkline
35
Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Dupont Pharmaceuticals